Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
510 participants
INTERVENTIONAL
2005-06-30
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
epratuzumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has SLE with at least one elevated lupus antibody;
* Has new onset of severe lupus disease flare in at least one body or organ system, excluding renal or neurologic
Exclusion Criteria
* Allergy to murine or human antibodies
* Antiphospholid antibodies AND a history of thrombocytopenic events
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna Barry
Role: STUDY_DIRECTOR
UCB Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Tucson, Arizona, United States
Los Angeles, California, United States
Upland, California, United States
Denver, Colorado, United States
Washington D.C., District of Columbia, United States
Baltimore, Maryland, United States
New York, New York, United States
The Bronx, New York, United States
Durham, North Carolina, United States
Winston-Salem, North Carolina, United States
Tulsa, Oklahoma, United States
Charleston, South Carolina, United States
Brussels, , Belgium
Debrecen, , Hungary
Amsterdam, , Netherlands
Santander, , Spain
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT #: 2005-000705-59
Identifier Type: -
Identifier Source: secondary_id
SL0003 (IMMU-103-03)
Identifier Type: -
Identifier Source: org_study_id